Tag: 9.3M
-
Antiverse secures $9.3M Series A for AI antibody platform
UK-based Antiverse, a biotech company developing AI-designed therapeutic antibodies for hard-to-target disease targets, has closed a $9.3 million Series A round led by Soulmates Ventures, with participation from Innovation Investment Capital, DOMiNO Ventures and existing investors DBW, Kadmos Capital and i&i Biotech Fund. The financing brings Antiverse’s total capital raised to more than $20 million. read more
Written by
